Physician profile
Mark H Shapiro
NPI 1912962275
$22,473.75
in general payments reported to CMS, 2019-2025
12 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,791 · 2020: $1,066 · 2021: $8,200 · 2022: $4,098 · 2023: $6,738 · 2024: $252 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,200 · Food and Beverage: $1,062 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $900 · Travel and Lodging: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,200.00 |
| Food and Beverage | $1,061.90 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $900.00 |
| Travel and Lodging | $156.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $14,926.13 | 2019-2023 | |
| Baxter Healthcare | $6,382.67 | 2019-2023 | Renal - Pd |
| Vantive US Healthcare LLC | $327.72 | 2025 | Renal - Pd |
| Nxstage Medical, INC. | $282.49 | 2023-2024 | Nxstage System One |
| Dexcom, INC. | $151.06 | 2023 | Dexcom G7 Gss (161) |
| Bard Peripheral Vascular, INC. | $117.88 | 2023 | Wavelinq |
| Amgen INC. | $72.43 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $64.33 | 2019 | |
| Akebia Therapeutics INC | $45.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.98 | 2024 | |
| Opko Pharmaceuticals, LLC | $38.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $20.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.